NASDAQ$GOCO
GoHealth Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
GoHealth's financial performance remained relatively stable with a slight revenue decrease, while submissions increased significantly. Net loss and Adjusted EBITDA improved, indicating progress towards profitability.
GoHealth reported a slight decrease in net revenues for Q3 2023, but saw a significant increase in submissions. The company's net loss and Adjusted EBITDA improved compared to the prior year period. GoHealth is focused on its Encompass solution and operational excellence to drive future growth and profitability.
- Net revenues for Q3 2023 were $132.0 million, slightly down from $133.1 million in the prior year period.
- Submissions increased by 31% to 161,550 in Q3 2023, compared to 122,964 in the prior year period.
- Net loss for Q3 2023 improved to $56.2 million, compared to $74.7 million in the prior year period.
- Adjusted EBITDA for Q3 2023 improved to negative $11.5 million, compared to negative $14.3 million in the prior year period.
Headline financials
Revenue & EPS history
GoHealth · Revenue · Quarterly
$132M
Revenue by segment
GoHealth · $11.9M total across 4 segments · Q1 2026
- Medicare Agency Revenue$9.8M—82.2%
- Other Non-Agency Revenue$1.76M—14.8%
- Medicare Non-Agency Revenue$200K—1.7%
- Other Agency Revenue$155K—1.3%
Forward guidance
GoHealth anticipates sustained growth and value delivery to shareholders, focusing on the Encompass model and operational excellence for future quarters.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2023
-7.7%
Avg return
Earnings day
-9.7%
Avg return
5 days after
-6.6%
Avg return
30 days after
26%
6 / 23 earnings
Positive
+32.2%
Q1 2023
Best reaction
-45.5%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.5% | -23.4% | — | |
| Q3 2025 | -24.4% | -32.0% | -12.8% | |
| Q2 2025 | -9.0% | -7.6% | -23.8% | |
| Q1 2025 | -0.6% | -17.4% | -21.4% | |
| Q4 2024 | -14.4% | -14.9% | -32.8% | |
| Q3 2024 | -6.6% | -0.4% | -15.4% | |
| Q2 2024 | -21.4% | -28.3% | -34.0% | |
| Q1 2024 | -8.0% | -11.1% | +2.2% | |
| Q4 2023 | -13.0% | -25.7% | -27.0% | |
| Q3 2023 | +2.3% | +6.7% | +7.4% | |
| Q2 2023 | +6.8% | +6.3% | -17.2% | |
| Q1 2023 | +32.2% | +44.8% | +99.5% | |
| Q4 2022 | -19.9% | -6.2% | -18.5% | |
| Q3 2022 | -16.7% | -9.4% | +95.3% | |
| Q2 2022 | -31.5% | -43.3% | -57.0% | |
| Q1 2022 | +11.1% | +4.9% | +6.5% | |
| Q4 2021 | +23.7% | +37.7% | -9.8% | |
| Q3 2021 | +1.1% | -4.7% | -18.1% | |
| Q2 2021 | -45.5% | -42.2% | -34.7% | |
| Q1 2021 | -2.7% | -5.6% | -4.0% | |
| Q4 2020 | -14.9% | -16.9% | -4.1% | |
| Q3 2020 | -14.9% | -15.1% | +1.8% | |
| Q2 2020 | -10.5% | -18.5% | -27.1% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro